<DOC>
	<DOC>NCT01438775</DOC>
	<brief_summary>This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207 in an earlier U.S. clinical trial of NX-1207.</brief_summary>
	<brief_title>Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>Be male aged 45 or older. Sign an informed consent form. Be in good health. Received NX1207 in a previous completed study or received NX1207 or placebo in a concurrent U.S. study (NX020017 and NX020018) and completed their V10 (365 day) visit. Have Prostate Gland Volume ≥ 25 mL (25 g). Surgery or minimally invasive surgical therapy (MIST) for treatment of BPH after first NX1207 injection Postvoid residual urine volume &gt; 200 mL Presence of a symptomatic median lobe of the prostate History of use of selfcatheterization for urinary retention. Urinary retention in the previous 12 months. Prostatitis Urinary tract infection more than once in the past 12 months Prostate or bladder cancer. PSA ≥10 ng/mL Poorly controlled diabetes History or evidence of illness or condition that may interfere with study or endanger subject Participation in a study of any investigational drug (other than NX1207) or investigational device within the previous 90 days Use of specific prescribed medications that may interfere with study or endanger subject</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>Enlarged prostate</keyword>
	<keyword>Lower urinary tract symptoms</keyword>
	<keyword>LUTS</keyword>
	<keyword>LUTS secondary to BPH</keyword>
	<keyword>LUTS/BPH</keyword>
	<keyword>Benign prostatic obstruction</keyword>
	<keyword>BPO</keyword>
	<keyword>Bladder outlet obstruction</keyword>
	<keyword>BOO</keyword>
</DOC>